Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
About
This Notice of Funding Opportunity (NOFO) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-Designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-Designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this NOFO are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.
The Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional) is a federal funding opportunity designed to support comprehensive, clinical, and basic cancer research centers across the United States. This grant program funds institutions that demonstrate excellence in cancer research across multiple scientific domains, including basic laboratory research, clinical research, and prevention/control/population-based research. CCSGs are specifically intended for institutions seeking NCI designation as Cancer Centers, which serve as major hubs for cancer discovery and the development of innovative prevention, diagnostic, and therapeutic approaches. The program supports the creation and maintenance of Shared Resources that benefit the broader research community, encourages transdisciplinary collaboration across institutional boundaries, and facilitates coordination with other NCI-funded programs. Institutions with substantial cancer research portfolios and the capacity to integrate research efforts across multiple departments and centers should consider applying. This grant is essential for academic medical centers, research institutions, and cancer-focused organizations aiming to establish or maintain their status as premier NCI-designated Cancer Centers while advancing the nation's cancer research agenda.
Funding Facts
● Applications openDeadline
September 25, 2028
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by Cancer Center type and institutional funding base
Deadline
2028-09-25
Grant Type
federal
Application Cycle
Annual (Deadline: September 25, 2028)
Best For
Research institutions, academic medical centers, and organizations seeking NCI-designated Cancer Center status
Eligibility
Specific to this NOFO:For New (Type 1) applications, an applicant institution must have a funding base of $10,000,000 (Clinical Cancer Centers) or $6,000,000 (Basic Cancer Centers) in annual direct costs of NIH funding that is cancer-focused, as defined by the Research Condition and Disease Categorization (RCDC) system. Please contact the NCI Office of Cancer Centers (https://cancercenters.cancer.
Frequently Asked Questions
Who is eligible for Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)?
For new (Type 1) applications, institutions must have a funding base of at least $10,000,000 in annual direct costs of NIH cancer-focused funding (for Clinical Cancer Centers) or $6,000,000 (for Basic Cancer Centers), as defined by the Research Condition and Disease Categorization (RCDC) system. The program supports three types of centers: Comprehensive Cancer Centers, Clinical Cancer Centers, and Basic Cancer Centers. For complete eligibility requirements and clarification, contact the NCI Office of Cancer Centers or visit the official NOFO on the NIH grants website.
How much funding does Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional) provide?
Specific funding amounts for this grant cycle have not been provided in the available information. Grant amounts typically vary based on the type of Cancer Center designation (Comprehensive, Clinical, or Basic), institutional research portfolio, and available appropriations. Contact the NCI Office of Cancer Centers or consult the official NOFO for current funding ranges and award details.
How do I apply for Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)?
Applications for CCSGs must be submitted through the NIH grants application system (Grants.gov). The application deadline for this cycle is September 25, 2028. Prospective applicants should review the complete Notice of Funding Opportunity (NOFO) on the NIH website, gather required institutional documentation demonstrating cancer research capacity and NIH funding base, and coordinate with their institution's grants office. Contact the NCI Office of Cancer Centers at https://cancercenters.cancer.gov for technical assistance and detailed submission requirements.
What can Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional) funding be used for?
CCSG funds support the integrated operations of NCI-designated Cancer Centers, including: research infrastructure and Shared Resources that benefit multiple investigators and research programs; transdisciplinary research initiatives that bridge basic laboratory, clinical, and population-based research; coordination and collaboration with other NCI-funded programs; scientific direction and administrative leadership; research dissemination and community engagement; and core facilities that support cancer research. Funds enable institutions to develop comprehensive, coordinated cancer research enterprises that advance discovery in prevention, diagnosis, and treatment.
Last updated: July 5, 2026